XML 28 R22.htm IDEA: XBRL DOCUMENT v3.26.1
License and Collaboration Agreements (Tables)
 6 Months Ended
Jun. 30, 2026
License And Collaboration Agreements [Abstract]  
Summary of Research and Development Costs Related to Collaboration and License Agreements The following table summarizes each party’s respective share of costs incurred and paid by the other party for zipalertinib development activities for the three and six months ended June 30, 2026 and 2025 (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Cullinan's share of zipalertinib research and development costs incurred by Taiho

 

$

6,618

 

 

$

7,772

 

 

$

12,428

 

 

$

13,390

 

Cullinan’s share of general and administrative costs incurred by Taiho

 

$

1,005

 

 

$

592

 

 

$

1,671

 

 

$

1,064

 

Taiho’s share of research and development costs incurred by Cullinan

 

$

652

 

 

$

3,112

 

 

$

1,474

 

 

$

4,486